Montelukast exerts no acute direct effect on NO synthases

Jürg Hamacher, Katja Eichert, Clemens Braun, Thomas Grebe, Andreas Strub, Rudolf Lucas, Manfrid Eltze, Albrecht Wendel

Research output: Contribution to journalArticle

1 Citation (Scopus)

Abstract

The cysteinyl leukotrienes (CysLTs) LTC4, LTD4 and LTE4 are potent proinflammatory lipid mediators that play a central role in inflammation, contraction and remodelling of airways observed in asthmatics. Montelukast, a competitive inhibitor of the cysteinyl leukotriene-1 (CysLT1) receptor attenuates asthmatic airway inflammation, contraction and remodelling. As a number of studies have shown that montelukast reduced exhaled nitric oxide (NO) levels, a marker of inflammation that correlates with the severity of asthma, we investigated whether or not a direct inhibition of NO synthase (NOS) by montelukast takes place. In an ex vivo rat lung perfusion and ventilation model the NOS-dependent vasodilation effect after lipopolysaccharide (LPS) infusion was assessed with and without montelukast. Functional organ bath studies using isolated aortic rings from the same species aimed to assess effects of montelukast on the inducible and endothelial NOS isoenzymes (i- and eNOS) as well as on iNOS expression. Neuronal NOS (nNOS) was assessed by field stimulated rabbit corpus cavernosum, and isolated human iNOS enzyme activity was assessed for potential inhibition. Montelukast failed to cause vasoconstriction in LPS challenged rat lung, or to inhibit i- and eNOS activity as well as iNOS expression in aortic rings from the same species. Also the assays for nNOS in rabbit corpus cavernosum and on isolated human iNOS enzyme gave no evidence for a direct inhibition by montelukast in physiological and supraphysiological concentrations up to 10-4 M. We therefore conclude that montelukast has no acute NOS inhibitor action. Its effect on exhaled NO is therefore probably indirectly mediated by a modulation of the asthmatic airway inflammation.

Original languageEnglish (US)
Pages (from-to)525-533
Number of pages9
JournalPulmonary Pharmacology and Therapeutics
Volume20
Issue number5
DOIs
StatePublished - Oct 1 2007

Fingerprint

montelukast
Nitric Oxide Synthase
Inflammation
Isoenzymes
Lipopolysaccharides
Rats
Nitric Oxide
Leukotriene E4
Rabbits
Airway Remodeling
Leukotriene D4
Enzyme inhibition
Leukotriene C4
Lung
Enzyme activity
Enzymes
Vasoconstriction
Baths
Vasodilation

Keywords

  • Leukotrienes
  • Lung vascular resistance
  • Montelukast
  • Nitric oxide synthases

ASJC Scopus subject areas

  • Pulmonary and Respiratory Medicine
  • Biochemistry, medical
  • Pharmacology (medical)

Cite this

Hamacher, J., Eichert, K., Braun, C., Grebe, T., Strub, A., Lucas, R., ... Wendel, A. (2007). Montelukast exerts no acute direct effect on NO synthases. Pulmonary Pharmacology and Therapeutics, 20(5), 525-533. https://doi.org/10.1016/j.pupt.2006.05.001

Montelukast exerts no acute direct effect on NO synthases. / Hamacher, Jürg; Eichert, Katja; Braun, Clemens; Grebe, Thomas; Strub, Andreas; Lucas, Rudolf; Eltze, Manfrid; Wendel, Albrecht.

In: Pulmonary Pharmacology and Therapeutics, Vol. 20, No. 5, 01.10.2007, p. 525-533.

Research output: Contribution to journalArticle

Hamacher, J, Eichert, K, Braun, C, Grebe, T, Strub, A, Lucas, R, Eltze, M & Wendel, A 2007, 'Montelukast exerts no acute direct effect on NO synthases', Pulmonary Pharmacology and Therapeutics, vol. 20, no. 5, pp. 525-533. https://doi.org/10.1016/j.pupt.2006.05.001
Hamacher, Jürg ; Eichert, Katja ; Braun, Clemens ; Grebe, Thomas ; Strub, Andreas ; Lucas, Rudolf ; Eltze, Manfrid ; Wendel, Albrecht. / Montelukast exerts no acute direct effect on NO synthases. In: Pulmonary Pharmacology and Therapeutics. 2007 ; Vol. 20, No. 5. pp. 525-533.
@article{f72292db9c52422fafc9e6bac35741a8,
title = "Montelukast exerts no acute direct effect on NO synthases",
abstract = "The cysteinyl leukotrienes (CysLTs) LTC4, LTD4 and LTE4 are potent proinflammatory lipid mediators that play a central role in inflammation, contraction and remodelling of airways observed in asthmatics. Montelukast, a competitive inhibitor of the cysteinyl leukotriene-1 (CysLT1) receptor attenuates asthmatic airway inflammation, contraction and remodelling. As a number of studies have shown that montelukast reduced exhaled nitric oxide (NO) levels, a marker of inflammation that correlates with the severity of asthma, we investigated whether or not a direct inhibition of NO synthase (NOS) by montelukast takes place. In an ex vivo rat lung perfusion and ventilation model the NOS-dependent vasodilation effect after lipopolysaccharide (LPS) infusion was assessed with and without montelukast. Functional organ bath studies using isolated aortic rings from the same species aimed to assess effects of montelukast on the inducible and endothelial NOS isoenzymes (i- and eNOS) as well as on iNOS expression. Neuronal NOS (nNOS) was assessed by field stimulated rabbit corpus cavernosum, and isolated human iNOS enzyme activity was assessed for potential inhibition. Montelukast failed to cause vasoconstriction in LPS challenged rat lung, or to inhibit i- and eNOS activity as well as iNOS expression in aortic rings from the same species. Also the assays for nNOS in rabbit corpus cavernosum and on isolated human iNOS enzyme gave no evidence for a direct inhibition by montelukast in physiological and supraphysiological concentrations up to 10-4 M. We therefore conclude that montelukast has no acute NOS inhibitor action. Its effect on exhaled NO is therefore probably indirectly mediated by a modulation of the asthmatic airway inflammation.",
keywords = "Leukotrienes, Lung vascular resistance, Montelukast, Nitric oxide synthases",
author = "J{\"u}rg Hamacher and Katja Eichert and Clemens Braun and Thomas Grebe and Andreas Strub and Rudolf Lucas and Manfrid Eltze and Albrecht Wendel",
year = "2007",
month = "10",
day = "1",
doi = "10.1016/j.pupt.2006.05.001",
language = "English (US)",
volume = "20",
pages = "525--533",
journal = "Pulmonary Pharmacology and Therapeutics",
issn = "1094-5539",
publisher = "Academic Press Inc.",
number = "5",

}

TY - JOUR

T1 - Montelukast exerts no acute direct effect on NO synthases

AU - Hamacher, Jürg

AU - Eichert, Katja

AU - Braun, Clemens

AU - Grebe, Thomas

AU - Strub, Andreas

AU - Lucas, Rudolf

AU - Eltze, Manfrid

AU - Wendel, Albrecht

PY - 2007/10/1

Y1 - 2007/10/1

N2 - The cysteinyl leukotrienes (CysLTs) LTC4, LTD4 and LTE4 are potent proinflammatory lipid mediators that play a central role in inflammation, contraction and remodelling of airways observed in asthmatics. Montelukast, a competitive inhibitor of the cysteinyl leukotriene-1 (CysLT1) receptor attenuates asthmatic airway inflammation, contraction and remodelling. As a number of studies have shown that montelukast reduced exhaled nitric oxide (NO) levels, a marker of inflammation that correlates with the severity of asthma, we investigated whether or not a direct inhibition of NO synthase (NOS) by montelukast takes place. In an ex vivo rat lung perfusion and ventilation model the NOS-dependent vasodilation effect after lipopolysaccharide (LPS) infusion was assessed with and without montelukast. Functional organ bath studies using isolated aortic rings from the same species aimed to assess effects of montelukast on the inducible and endothelial NOS isoenzymes (i- and eNOS) as well as on iNOS expression. Neuronal NOS (nNOS) was assessed by field stimulated rabbit corpus cavernosum, and isolated human iNOS enzyme activity was assessed for potential inhibition. Montelukast failed to cause vasoconstriction in LPS challenged rat lung, or to inhibit i- and eNOS activity as well as iNOS expression in aortic rings from the same species. Also the assays for nNOS in rabbit corpus cavernosum and on isolated human iNOS enzyme gave no evidence for a direct inhibition by montelukast in physiological and supraphysiological concentrations up to 10-4 M. We therefore conclude that montelukast has no acute NOS inhibitor action. Its effect on exhaled NO is therefore probably indirectly mediated by a modulation of the asthmatic airway inflammation.

AB - The cysteinyl leukotrienes (CysLTs) LTC4, LTD4 and LTE4 are potent proinflammatory lipid mediators that play a central role in inflammation, contraction and remodelling of airways observed in asthmatics. Montelukast, a competitive inhibitor of the cysteinyl leukotriene-1 (CysLT1) receptor attenuates asthmatic airway inflammation, contraction and remodelling. As a number of studies have shown that montelukast reduced exhaled nitric oxide (NO) levels, a marker of inflammation that correlates with the severity of asthma, we investigated whether or not a direct inhibition of NO synthase (NOS) by montelukast takes place. In an ex vivo rat lung perfusion and ventilation model the NOS-dependent vasodilation effect after lipopolysaccharide (LPS) infusion was assessed with and without montelukast. Functional organ bath studies using isolated aortic rings from the same species aimed to assess effects of montelukast on the inducible and endothelial NOS isoenzymes (i- and eNOS) as well as on iNOS expression. Neuronal NOS (nNOS) was assessed by field stimulated rabbit corpus cavernosum, and isolated human iNOS enzyme activity was assessed for potential inhibition. Montelukast failed to cause vasoconstriction in LPS challenged rat lung, or to inhibit i- and eNOS activity as well as iNOS expression in aortic rings from the same species. Also the assays for nNOS in rabbit corpus cavernosum and on isolated human iNOS enzyme gave no evidence for a direct inhibition by montelukast in physiological and supraphysiological concentrations up to 10-4 M. We therefore conclude that montelukast has no acute NOS inhibitor action. Its effect on exhaled NO is therefore probably indirectly mediated by a modulation of the asthmatic airway inflammation.

KW - Leukotrienes

KW - Lung vascular resistance

KW - Montelukast

KW - Nitric oxide synthases

UR - http://www.scopus.com/inward/record.url?scp=34447559355&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=34447559355&partnerID=8YFLogxK

U2 - 10.1016/j.pupt.2006.05.001

DO - 10.1016/j.pupt.2006.05.001

M3 - Article

C2 - 16815057

AN - SCOPUS:34447559355

VL - 20

SP - 525

EP - 533

JO - Pulmonary Pharmacology and Therapeutics

JF - Pulmonary Pharmacology and Therapeutics

SN - 1094-5539

IS - 5

ER -